 Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd NASDAQ: ENTX has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month open-label transition to alendronate for all patients. The studys primary. 